Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

Diabetes Care

Volumn 27, Issue 12, 2004, Pages 2874-2880

  Ahrén, Bo ^a   Gomis, Ramon ^b   Standl, Eberhard ^c   Mills, David ^d   Schweizer, Anja ^d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; METFORMIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADULT; ARTICLE; BURSITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STATISTICAL SIGNIFICANCE;

ADAMANTANE; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; PROTEASE INHIBITORS; PYRROLIDINES;

EID: 9444285818     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.12.2874     Document Type: Article

References (19)

1. Dardik B, Valentin M, Schwarztkopf C, Gutierrez C, Stevens D, Russell M, Edwin V, Hughes T: NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys (Abstract). Diabetes 52 (Suppl. 1):A322, 2003
2. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE: 1-[[(3-hydroxy-1-adamantyl)amino-]acetyl]-2- cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789, 2003
3. Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084, 2004
4. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickmson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875, 2002
5. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
6. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377, 2003
7. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ: Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24:720-725, 2001
8. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408, 2002
9. Trumper A, Trumper K, Trusheim H, Arnold R, Göke B, Horsch D: Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15:1559-1570, 2001
10. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H: Glucose tolerance and insulin release, a mathematical approach. 1. Assay of the beta-cell response after oral glucose loading. Diabetes 25:241-244, 1976
11. Sluiter WJ, Erkelens DW, Terpstra P, Reitsma WD, Doorenbos H: Glucose tolerance and insulin release, a mathematical approach. II. Approximation of the peripheral insulin resistance after oral glucose loading. Diabetes 25:245-249, 1976
12. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Foley JE: LAF237 is a DPP-4 inhibitor that improves model-assessed β-cell function in drug-naive patients with type 2 diabetes. Diabetologia. In press
13. Ahrén B, Holst JJ, Mari A: Characterization of GLP-1 effects on β-cell function after meal ingestion in humans. Diabetes Care 26:2860-2864, 2003
14. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304, 1987
15. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessto DA: Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26: 791-798, 2003
16. Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386, 2003
17. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
18. Bonadonna RC, Stumvoll M, Fritsche A, Muggeo M, Haring H, Bonora E, van Haeften TW: Altered homeostatic adaptation of first- and second-phase β-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess β-cell function. Diabetes 52:470-480, 2003
19. Mart A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E: Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159-E1166, 2002